

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 January 2001 (04.01.2001)

PCT

(10) International Publication Number
WO 01/00585 A1

(51) **International Patent Classification⁷:** C07D 231/32,
231/30, A61K 31/4152, A61P 31/08, 37/06

(NO). KLAVENESS, Jo [NO/NO]; A-Viral AS, Karihaugveien 102, N-1006 Oslo (NO).

(21) **International Application Number:** PCT/GB00/02513

(74) **Agents:** COCKBAIN, Julian et al.; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).

(22) **International Filing Date:** 29 June 2000 (29.06.2000)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**
9915184.7 29 June 1999 (29.06.1999) GB

(71) **Applicant (for all designated States except US):** A-VIRAL AS [NO/NO]; Karihaugveien 102, N-1006 Oslo (NO).

(81) **Designated States (national):** AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) **Applicant (for GB only):** COCKBAIN, Julian [GB/GB]; Flat 4, 83 Linden Gardens, London W2 4EU (GB).

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


(72) **Inventors; and**

(75) **Inventors/Applicants (for US only):** TJØTTA, Enok [NO/NO]; A-Viral AS, Karihaugveien 102, N-1006 Oslo

[Continued on next page]

(54) **Title:** PYRAZOLIDINOL COMPOUNDS

THE EFFECT OF DIFFERENT CONCENTRATIONS OF
4-HYDROXY-OXYPHENBUTAZONE COMPARED TO PHENBUTAZONE



(57) **Abstract:** The invention provides the use of an optionally hydroxy-protected 4-hydroxy or hydroperoxy-3,5-dioxypyrazolidine or an equivalent wherein a pyrazolidine ring attached oxygen is replaced by a sulphur, or a physiologically acceptable salt thereof, for the manufacture of a medicament for use in therapy or prophylaxis. Additionally, the invention provides a method of combatting HIV infection which comprises administering to an HIV-infected patient a T-lymphocyte growth suppressing agent, preferably a pyrazolidinol, in an amount sufficient to suppress T-lymphocyte growth in said patient for a period sufficient to reduce the T-lymphocyte concentration in lymph nodes in said patient by at least 25 % said administration being repeated at intervals of at least 3 months.

WO 01/00585 A1

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.